Skip to content

Oxygen Reserve Index (ORi) Validation of INVSENSOR00014

Oxygen Reserve Index (ORi) Validation of INVSENSOR00014

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03500341
Enrollment
33
Registered
2018-04-18
Start date
2018-03-21
Completion date
2018-08-01
Last updated
2021-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

The Oxygen Reserve Index (ORi) is a reference that could help clinicians with their assessments of normoxic and hyperoxic states by scaling the measured absorption information between 0.00 and 1.00. An ORi of 0.00 corresponds to PaO2 values of 100mmHg and below and an ORi of 1.00 corresponds to PaO2 values of 200mmHg and above.) In this study, the PaO2 is varied by controlling the concentration of oxygen the study volunteer breathes. The ORI device measurement is analyzed by comparing it to the PaO2 measurements from blood samples from a laboratory analyzer.

Interventions

DEVICEINVSENSOR00014

Noninvasive pulse oximeter sensor

Sponsors

Masimo Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject is 18-50 years of age. * Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall. * Hemoglobin value is greater than or equal to 11 g/dL. * Baseline heart rate greater than or equal to 45 bpm and less than or equal to 85 bpm. * Carbon monoxide (CO) value less than or equal to 2.0% fractional carboxyhaemoglobin (FCOHb) * Subject has a physical status of American Society of Anesthesiology Class 1 (ASA I, Healthy subjects without any systemic disease at all.) American Society of Anesthesiology Class 2 (ASA II, subjects with mild systemic disease) as it applies to the systemic disease portion of the classification. * Systolic Blood Pressure less than or equal to 140 mmHg and Diastolic Blood Pressure less than or equal to 90 mmHg. * Subject is able to read and communicate in English and understands the study and risks involved.

Exclusion criteria

* Subject is pregnant. * Subject smokes (smoking includes e-cigarette use) * Subject has a BMI \> 35 and has been classified as morbidly obese or at an increased risk for participation by a medical professional. * Subject has open wounds, inflamed tattoos or piercings or any visible healing wounds. * Subject experiences frequent or severe headaches and/or migraine headaches. * Subject has known drug or alcohol abuse or uses recreational drugs. * Subject has experienced a concussion or head injury with loss of consciousness within the last year. * Subject has any chronic bleeding disorders (i.e. hemophilia) * Subject has any history of a stroke, myocardial infarction, seizures or heart attack. * Subject has any cancer or history of cancer (not including skin cancer). * Subject has a chronic neurological disease (i.e. multiple sclerosis, Huntington's disease). * Subject has any cardiac dysrhythmia(s) (i.e. atrial fibrillation) and has not received clearance from their physician to participate. * Subject has known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder) that interferes with the subjects' level of consciousness. * Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study (Discretion of investigator). * Subject has Wolff-Parkinson-White Syndrome or Stokes - Adams syndrome. * Subject who has taken anticoagulant medications within the last 30 days. * Subject has taken opioid pain medication within 24 hours of start of study. * Subject has either signs or history of peripheral ischemia or carpal tunnel syndrome. * Subject has had invasive surgery within the past year- including but not limited to major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving plates/ screws), jaw surgery, urinary tract surgery, plastic surgery, major ear nose or throat (ENT) surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery. * Subject has donated blood within the last 2 weeks. * Subject has symptoms of congestion, head colds, flu or other illnesses. * Subject experiences claustrophobia or has generalized anxiety disorder. * Subject has been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the last 12 months. * Subject has had a concussion within the past 12 months. * Subject has chronic unresolved asthma, lung disease or respiratory disease. * Subject is allergic to lidocaine, latex, adhesives, or plastic. * Subject has heart conditions, insulin-dependent Diabetes or uncontrolled hypertension. * Subject has given vaginal delivery, had a pregnancy terminated, a miscarriage with hospitalization, or had a cesarean section (C-section) within the past 6 months. * Subject intends to participate in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours of the study. * Discretion of investigator/study staff.

Design outcomes

Primary

MeasureTime frameDescription
Specificity, Sensitivity, and Concordance for the ORi Measurement System as Compared to PaO21-5 hours per subjectThis study reports ORi specificity, sensitivity and concordance for Masimo's ORi measurement system as compared to PaO2 from blood samples.

Countries

United States

Participant flow

Pre-assignment details

Of the 33 enrolled participants, 16 met inclusion criteria and proceeded to the study. The remainder of the enrolled participants include screen failures and subjects that did not proceed due to time constraints.

Participants by arm

ArmCount
Test Subject
All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00014 sensor INVSENSOR00014: Noninvasive pulse oximeter sensor
14
Total14

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyWithdrawn prior to Completion2

Baseline characteristics

CharacteristicTest Subject
Age, Customized
18 to 50 years old
14 Participants
Age, Customized
< 18 years old
0 Participants
Age, Customized
> 50 years old
0 Participants
Race/Ethnicity, Customized
Asian or Pacific Islander
2 Participants
Race/Ethnicity, Customized
Black or African American
3 Participants
Race/Ethnicity, Customized
Caucasian
4 Participants
Race/Ethnicity, Customized
Hispanic
3 Participants
Race/Ethnicity, Customized
Native American
2 Participants
Sex: Female, Male
Female
4 Participants
Sex: Female, Male
Male
10 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 16
other
Total, other adverse events
0 / 16
serious
Total, serious adverse events
0 / 16

Outcome results

Primary

Specificity, Sensitivity, and Concordance for the ORi Measurement System as Compared to PaO2

This study reports ORi specificity, sensitivity and concordance for Masimo's ORi measurement system as compared to PaO2 from blood samples.

Time frame: 1-5 hours per subject

Population: Sufficient number of cases to meet sample size criteria for assessing outcomes was not achieved. The protocol required a minimum of 22 completed subjects. This study was not able to meet this target and therefore the specificity, sensitivity and concordance for Masimo's ORi measurement system could not be defined (primary outcome measure).

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026